Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
DNP – Die Neurologie & Psychiatrie
Erschienen in: DNP - Der Neurologe & Psychiater 4/2017

04.04.2017 | Multiple Sklerose | Zertifizierte Fortbildung

Chronisch-entzündliche Autoimmunerkrankungen des ZNS

Therapie der primär und sekundär chronisch-progredienten MS

verfasst von: Dr. med. Sibylle C. Hodecker, Prof. Dr. med. Manuel A. Friese

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die für die schubförmige Multiple Sklerose (MS) zugelassenen immunmodulierenden und -supprimierenden Therapien zeigen bei der chronisch-progredienten Verlaufsform wenig oder keine Wirksamkeit. Die niedrige Wirksamkeit antientzündlicher Wirkstoffe in der Therapie der chronisch-progredienten MS im Vergleich zur schubförmig-remittierenden MS ist vermutlich durch die unterschiedliche Akzentuierung pathogenetischer Veränderungen der Verlaufsformen begründet.
Literatur
1.
Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor B V., et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014 Sep 9;83(11):1022–4.CrossRefPubMedPubMedCentral
2.
Hein T, Hopfenmüller W. [Projection of the number of multiple sclerosis patients in Germany]. Nervenarzt. 2000 Apr;71(4): 288–94.CrossRefPubMed
3.
Petersen G, Wittmann R, Arndt V, Göpffarth D. Epidemiologie der Multiplen Sklerose in Deutschland. Nervenarzt. 2014 Aug 16;85(8):990–8.CrossRefPubMed
4.
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015 Aug 7;15(9):545–58.CrossRefPubMed
5.
Popescu BFG, Lucchinetti CF. Pathology of Demyelinating Diseases. Annu Rev Pathol Mech Dis. 2012 Feb 28;7(1):185–217.CrossRef
6.
Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, Romualdi C, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain. 2012 Oct 1;135(10):2952–61.CrossRefPubMed
7.
Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011 Sep 1;134(9):2755–71.CrossRefPubMed
8.
Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet (London, England). 2016 Nov 23; Epub ahead of print. DOI: 10.1016/S0140-6736(16)31320-4.
9.
Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014 Mar 18;10(4):225–38.CrossRefPubMed
10.
Kappos L. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998 Nov 7;352(9139):1491–7.CrossRef
11.
Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004 Nov 23;63(10):1788–95.CrossRefPubMed
12.
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology. 2001 Jun 12;56(11):1496–504.CrossRef
13.
Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002 Sep 10;59(5):679–87.CrossRefPubMed
14.
Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003 Jan 14;60(1):44–51.CrossRefPubMed
15.
Montalban X, Sastre-Garriga J, Tintore M, Brieva L, Aymerich F, Rio J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009 Oct 1;15(10):1195–205.CrossRefPubMed
16.
Tur C, Montalban X, Tintoré M, Nos C, Río J, Aymerich FX, et al. Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis. Arch Neurol. 2011 Nov 1;68(11):1421.CrossRefPubMed
17.
Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007 Jan;61(1):14–24.CrossRefPubMed
18.
Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075–84.CrossRefPubMed
19.
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, et al. Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study. In: ECTRIMS. 2016. p. Abstract 250.
20.
Steiner D, Dl A, Ms F, Md G, Hp H, Havrdova E, et al. Natalizumab Versus Placebo in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Results from ASCEND, a Multicenter, Double-blind, Placebo-Controlled, Randomized Phase 3 Clinical Trial. In: 68th Annual Meeting of the American Academy of Neurology. 2016.
21.
Hartung H-P, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 Dec;360(9350):2018–25.CrossRefPubMed
22.
Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology. 1989 Aug;39(8):1018–26.CrossRefPubMed
23.
British And Dutch Multiple Sclerosis Azathioprine Trial Group. Double-Masked Trial of Azathioprine in Multiple Sclerosis. Lancet. 1988 Jul 23;332(8604):179–83.
24.
Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015 Feb 1;14(2):208–23.CrossRefPubMedPubMedCentral
25.
La Mantia L, Milanese C, Mascoli N, D’Amico R, Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002819.
26.
Goodkin DE, Kinkel RP, Weinstock-Guttman B, VanderBrug-Medendorp S, Secic M, Gogol D, et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology. 1998 Jul;51(1):239–45.CrossRefPubMed
27.
Hommes OR, Sørensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004 Sep;364(9440):1149–56.CrossRefPubMed
28.
Pohlau D, Przuntek H, Sailer M, Bethke F, Koehler J, Konig N, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler. 2007 Apr 27;13(9):1107–17.CrossRefPubMed
29.
Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct;66(4):460–71.CrossRefPubMed
30.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2016 Dec 21;Epub ahead of print. DOI: 10.1056/NEJMoa1606468
31.
Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014 Jun;383(9936):2213–21.CrossRefPubMed
32.
Schattling B, Fazeli W, Engeland B, Liu Y, Lerche H, Isbrandt D, et al. Activity of NaV1.2 promotes neurodegeneration in an animal model of multiple sclerosis. JCI Insight. 2016 Nov 17;1(19):e89810.CrossRefPubMedPubMedCentral
33.
Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci. 2006 Dec;7(12):932–41.CrossRefPubMed
34.
Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Mar;15(3):259–69.CrossRefPubMed
35.
Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 Jul;9(7):681–8.CrossRefPubMed
36.
Sedel F, Bernard D, Mock DM, Tourbah A. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. 2016 Nov;110(Pt B):644–53.CrossRefPubMed
37.
Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler J. 2016 Nov 1;22(13):1719–31.CrossRef
38.
Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem. 2001;81(4):715–23.CrossRefPubMed
39.
Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Med Sci. 1998;95:8268–73.
40.
Molina-Holgado E, Vela JM, Arévalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci. 2002 Nov 15;22(22):9742–53.PubMed
41.
Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3984–9.CrossRefPubMedPubMedCentral
42.
Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013 Sep;12(9):857–65.CrossRefPubMedPubMedCentral
43.
Cervellini I, Ghezzi P, Mengozzi M. Therapeutic Efficacy of Erythropoietin in Experimental Autoimmune Encephalomyelitis in Mice, a Model of Multiple Sclerosis. Methods Mol Biol. 2013;982:163–73.CrossRefPubMed
44.
Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002;952(1):128–34.CrossRefPubMed
45.
Zhang J, Li Y, Cui Y, Chen J, Lu M, Elias SB, et al. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 2005;1034(1):34–9.CrossRefPubMed
46.
Sättler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bähr M, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ. 2004 Dec 1;11:S181–92.CrossRefPubMed
47.
Sühs K-W, Hein K, Sättler MB, Görlitz A, Ciupka C, Scholz K, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012 Aug;72(2):199–210.CrossRefPubMed
48.
Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen CG, et al. High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Mult Scler J. 2016 Aug 1
49.
Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, et al. Efficacy Analysis of the Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: the RENEW Trial (P7.202). Neurology. 2015;84(14 Supplement):P7.202.
50.
Cadavid D, Edwards KR, Hupperts R, Drulović J, Montalban X, Hartung H-P, et al. Efficacy analysis of opicinumab in relapsing multiple sclerosis: the Phase 2b SYNERGY trial. In: ECTRIMS. 2016. p. Abstract 192.
51.
Windrem MS, Schanz SJ, Guo M, Tian G-F, Washco V, Stanwood N, et al. Neonatal Chimerization with Human Glial Progenitor Cells Can Both Remyelinate and Rescue the Otherwise Lethally Hypomyelinated Shiverer Mouse. Cell Stem Cell. 2008 Jun 5;2(6):553–65.CrossRefPubMedPubMedCentral
52.
53.
Najm FJ, Madhavan M, Zaremba A, Shick E, Karl RT, Factor DC, et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature. 2015 Apr 20;522(7555):216–20.CrossRefPubMedPubMedCentral
54.
Mei F, Fancy SPJ, Shen Y-AA, Niu J, Zhao C, Presley B, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med. 2014 Jul 6;20(8):954–60.CrossRefPubMedPubMedCentral
55.
Deshmukh VA, Tardif V, Lyssiotis CA, Green CC, Kerman B, Kim HJ, et al. A regenerative approach to the treatment of multiple sclerosis. Nature. 2013 Oct 9;502(7471):327–32.CrossRefPubMedPubMedCentral
56.
Friese MA, Craner MJ, Etzensperger R, Vergo S, Wemmie JA, Welsh MJ, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med. 2007 Dec 11;13(12):1483–9.CrossRefPubMed
57.
Schattling B, Steinbach K, Thies E, Kruse M, Menigoz A, Ufer F, et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2012 Nov 18;18(12):1805–11.CrossRefPubMed
58.
Green A, Gelfand J, Cree B, Bevan C, Boscardin W, Mei F, et al. Positive phase II double-blind randomized placebo-controlled crossover trial of clemastine fumarate for remyelination of chronic optic neuropathy in MS. In: Annual Meeting of the American Academy of Neurology. Vancouver, BC, Canada; 2016. p. Abstract ES1.008.
59.
Vesterinen HM, Connick P, Irvine CMJ, Sena ES, Egan KJ, Carmichael GG, et al. Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis. Fujinami RS, editor. PLoS One. 2015 Apr 9;10(4):e0117705.CrossRefPubMedPubMedCentral
60.
Campbell E, Coulter EH, Mattison PG, Miller L, McFadyen A, Paul L. Physiotherapy Rehabilitation for People With Progressive Multiple Sclerosis: A Systematic Review. Arch Phys Med Rehabil. 2016 Jan;97(1):141–151.e3.CrossRefPubMed
61.
Heesen AC, Stückrath E, Köpke S, Hauptmann B, Henze T, Heesen KC. Rehabilitation bei Multipler Sklerose in Deutschland — Ergebnisse einer Umfrage Rehabilitation in Multiple Sclerosis in Germany — Results of a Survey. Akt Neurol. 2009;22(37):4–9.
62.
Briken S, Gold S, Patra S, Vettorazzi E, Harbs D, Tallner A, et al. Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial. Mult Scler J. 2014 Mar 1;20(3):382–90.CrossRef
63.
Feys P. Potential of robot-assisted therapy for disabled persons with MS. Mult Scler. 2016 Mar 1;22(3):264–5.CrossRefPubMed
64.
Tomassini V, Matthews PM, Thompson AJ, Fuglø D, Geurts JJ, Johansen-Berg H, et al. Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol. 2012 Sep 18;8(11):635–46.CrossRefPubMedPubMedCentral
65.
Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015 Feb 1;14(2):194–207.CrossRefPubMed
66.
Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007 Apr 1;21(4):331–7.CrossRefPubMed
67.
Miller L, Mattison P, Paul L, Wood L. The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler. 2007 Jan 29;13(4):527–33.CrossRefPubMed
68.
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008 Jul 16;14(8):1076–83.CrossRefPubMed
69.
Ratchford JN, Shore W, Hammond ER, Rose JG, Rifkin R, Nie P, et al. A pilot study of functional electrical stimulation cycling in progressive multiple sclerosis. NeuroRehabilitation. 2010;27(2):121–8.PubMed
70.
Velikonja O, Čurić K, Ožura A, Jazbec SŠ. Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg. 2010 Sep;112(7):597–601.CrossRefPubMed
71.
Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex ® ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011 Sep;18(9):1122–31.CrossRefPubMed
72.
Yadav V, Bever C, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Mar 25;82(12):1083–92.CrossRefPubMedPubMedCentral
73.
Swinnen E, Beckwée D, Pinte D, Meeusen R, Baeyens J-P, Kerckhofs E. Treadmill Training in Multiple Sclerosis: Can Body Weight Support or Robot Assistance Provide Added Value? A Systematic Review. Mult Scler Int. 2012;2012:1–15.CrossRef
74.
Pilutti LA, Lelli DA, Paulseth JE, Crome M, Jiang S, Rathbone MP, et al. Effects of 12 Weeks of Supported Treadmill Training on Functional Ability and Quality of Life in Progressive Multiple Sclerosis: A Pilot Study. Arch Phys Med Rehabil. 2011 Jan;92(1):31–6.CrossRefPubMed
75.
Paltamaa J, Sjögren T, Peurala S, Heinonen A. Effects of physiotherapy interventions on balance in multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials. J Rehabil Med. 2012 Oct;44(10):811–23.CrossRefPubMed
76.
Latimer-Cheung AE, Pilutti LA, Hicks AL, Martin Ginis KA, Fenuta AM, MacKibbon KA, et al. Effects of Exercise Training on Fitness, Mobility, Fatigue, and Health-Related Quality of Life Among Adults With Multiple Sclerosis: A Systematic Review to Inform Guideline Development. Arch Phys Med Rehabil. 2013 Sep;94(9):1800–1828.e3.CrossRefPubMed
77.
Kjølhede T, Vissing K, Dalgas U. Multiple sclerosis and progressive resistance training: a systematic review. Mult Scler J. 2012 Sep;18(9):1215–28.CrossRef
78.
Snook EM, Motl RW. Effect of Exercise Training on Walking Mobility in Multiple Sclerosis: A Meta-Analysis. Neurorehabil Neural Repair. 2008 Nov 7;23(2):108–16.CrossRefPubMed
79.
Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. In: Mills RJ, editor. Cochrane Database of Systematic Reviews. 2007;(1):CD005029.
80.
Fonteyn EMR, Keus SHJ, Verstappen CCP, Schöls L, de Groot IJM, van de Warrenburg BPC. The effectiveness of allied health care in patients with ataxia: a systematic review. J Neurol. 2014 Feb 16;261(2):251–8.CrossRefPubMed
81.
Marquer A, Barbieri G, Pérennou D. The assessment and treatment of postural disorders in cerebellar ataxia: A systematic review. Ann Phys Rehabil Med. 2014 Mar;57(2):67–78.CrossRefPubMed
82.
De Ridder D, Van Poppel H, Baert L, Binard J. From time dependent intermittent selfcatheterisation to volume dependent selfcatheterisation in multiple sclerosis using the PCI 5000 Bladdermanager. Spinal Cord. 1997 Sep;35(9):613–6.CrossRefPubMed
83.
De Ridder D, Vermeulen C, Ketelaer P, Van Poppel H, Baert L. Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg. 1999 Mar;99(1):61–4.PubMed
84.
Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil. 2003 Feb;17(1):42–7.CrossRefPubMed
85.
Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial. Eur Urol. 2011 Oct;60(4):742–50.CrossRefPubMed
86.
van Rey F, Heesakkers J. Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study. Adv Urol. 2011;2011:1–5.
87.
Vanage et al., 2003: Vanage SM, Gilbertson KK, Mathiowetz V. Effects of an energy conservation course on fatigue impact for persons with progressive multiple sclerosis. Am J Occup Ther. 2003 May-Jun;57(3):315-23.
88.
Tejani et al., 2012: Tejani AM, Wasdell M, Spiwak R, Rowell G, Nathwani S. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007280.
89.
Blikman et al., 2013: Blikman LJ, Huisstede BM, Kooijmans H, Stam HJ, Bussmann JB, van Meeteren J. Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2013 Jul;94(7):1360-76.
90.
Pucci et al., 2007: Pucci E, Branãs P, D’Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002818.
91.
Pilutti et al., 2013: Pilutti LA, Greenlee TA, Motl RW, Nickrent MS, Petruzzello SJ. Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis. Psychosom Med. 2013 Jul-Aug;75(6):575-80.
92.
Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, DeLuca J. L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler J. 2011 Sep 1;17(9):1141–5.CrossRef
93.
Benedict RHB, Munschauer F, Zarevics P, Erlanger D, Rowe V, Feaster T, et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. J Neurol. 2008 Jun 16;255(6):848–52.CrossRefPubMed
94.
Krupp LB, Christodoulou C, Melville P, Scherl WF, Pai L-Y, Muenz LR, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. 2011 Apr 26;76(17):1500–7.CrossRefPubMedPubMedCentral
95.
Chiaravalloti ND, DeLuca J, Moore NB, Ricker JH. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult Scler. 2005 Feb;11(1):58–68.CrossRefPubMed
96.
Chiaravalloti ND, Moore NB, Nikelshpur OM, DeLuca J. An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial. Neurology. 2013 Dec 10;81(24):2066–72.CrossRefPubMedPubMedCentral
97.
Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, De Keyser J. Pharmacologic treatment of depression in multiple sclerosis. In: Koch MW, editor. Cochrane Database of Systematic Reviews. 2011;(16):CD007295.
98.
Thomas PW, Thomas S, Hillier C, Galvin K, Baker R. Psychological interventions for multiple sclerosis. Thomas PW, editor. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004431.
99.
Wier LM, Hatcher MS, Triche EW, Lo AC. Effect of robot-assisted versus conventional body-weight-supported treadmill training on quality of life for people with multiple sclerosis. J Rehabil Res Dev. 2011;48(4):483–92.CrossRefPubMed
100.
Warke K, Al-Smadi J, Baxter D, Walsh DM, Lowe-Strong AS. Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low-back Pain in a Multiple Sclerosis Population. Clin J Pain. 2006 Nov;22(9):812–9.CrossRefPubMed
101.
Negahban H, Rezaie S, Goharpey S. Massage therapy and exercise therapy in patients with multiple sclerosis: a randomized controlled pilot study. Clin Rehabil. 2013 Dec;27(12):1126–36.CrossRefPubMed
102.
Schyns F, Paul L, Finlay K, Ferguson C, Noble E. Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance. Clin Rehabil. 2009 Sep 1;23(9):771–81.CrossRefPubMed
103.
Solaro C, Trabucco E, Messmer Uccelli M. Pain and Multiple Sclerosis: Pathophysiology and Treatment. Curr Neurol Neurosci Rep. 2013 Jan 19;13(1):320.CrossRefPubMed
104.
Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732–8.CrossRefPubMed
105.
Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):773–80.CrossRefPubMedPubMedCentral
106.
De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010 Jun 8;74(23):1868–76.CrossRefPubMed
107.
Calabrese M, Rinaldi F, Grossi P, Gallo P. Cortical pathology and cognitive impairment in multiple sclerosis. Expert Rev Neurother. 2011 Mar 9;11(3):425–32.CrossRefPubMed
108.
Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage. 2004 Nov;23(3):1168–75.CrossRefPubMed
109.
Fisher E, Lee J-C, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol. 2008 Sep 28;64(3):255–65.CrossRefPubMed
110.
Mesaros S, Rocca MA, Pagani E, Sormani MP, Petrolini M, Comi G, et al. Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years. AJNR Am J Neuroradiol. 2011;32(6):1016–20.CrossRefPubMed
111.
Anderson V, Fisniku L, Khaleeli Z, Summers M, Penny S, Altmann D, et al. Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study. Mult Scler. 2010 Sep 1;16(9):1083–90.CrossRefPubMed
112.
Bieniek M, Altmann DR, Davies GR, Ingle GT, Rashid W, Sastre-Garriga J, et al. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006 Sep;77(9):1036–9.CrossRefPubMedPubMedCentral
Metadaten
Titel
Chronisch-entzündliche Autoimmunerkrankungen des ZNS
Therapie der primär und sekundär chronisch-progredienten MS
verfasst von
Dr. med. Sibylle C. Hodecker
Prof. Dr. med. Manuel A. Friese
Publikationsdatum
04.04.2017
Verlag
Springer Medizin
Schlagwort
Multiple Sklerose
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 4/2017
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-017-1496-y

Weitere Artikel der Ausgabe 4/2017

DNP - Der Neurologe & Psychiater 4/2017 Zur Ausgabe

Industrieforum

Tranylcypromin leichter dosieren

Industrieforum

ADHS: Affektstörungen in den Griff bekommen

Industrieforum

Dopaminagonisten bei RLS weiter erste Wahl

Industrieforum

Auch bei der MS gilt: „Time is Brain“

Industrieforum

G-BA: Alemtuzumab wirtschaftlich

Literatur kompakt

Gibt es ein bipolares Prodrom?
Bildnachweise